Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.

Scalp cooling effectively prevents severe hair loss in breast cancer patients treated with docetaxel and is safe.

Tamoxifen caused hair loss in a 52-year-old woman.

Breast cancer may be detectable through changes in scalp hair lipids.

Cinnamon bark extract may help prevent weight loss and hair loss in breast cancer patients during chemotherapy and is safe to use.

Hormone therapy for breast cancer often leads to sexual issues like vaginal dryness and decreased libido.

Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.

Docetaxel and paclitaxel for breast cancer can cause permanent, severe hair loss.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.

The androgen receptor is a promising target for breast cancer treatment, especially in triple-negative cases, but more research is needed for personalized therapies.

Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.

Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.

Research from 2011 to 2020 shows androgen receptors could be key for prognosis and treatment in certain breast cancers.

Patients with HR+/HER2- advanced breast cancer commonly experience fatigue, hair loss, and pain, which significantly affect daily activities.

Managing side effects of endocrine therapy is crucial to improve adherence and survival in breast cancer patients.

Non-hormonal treatments should be used first for sexual dysfunction in postmenopausal breast cancer patients on aromatase inhibitors, with hormones as a second option.

Low Vitamin D receptor levels in breast cancer are linked to worse outcomes and more bone metastases, and could be a marker for prognosis.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Some hormone treatments might raise breast cancer risk, while others don't seem to.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.

Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.

Keratin 18 helps diagnose and predict cancer progression and affects cancer growth and spread.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Etoposide is effective in treating several cancers, especially small cell lung cancer, with acceptable side effects.

PEGylated liposomal doxorubicin improves cancer treatment effectiveness and reduces side effects like heart damage and hair loss.

Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.